References
A. U. Ziganshin, L. E. Ziganshina, and G. Burnstock,Khim.-Farm. Zh.,31(1), 3–8 (1997).
B. B. Fredholm, M. P. Abbracchio, G. Burnstock, et al.,Trends Pharmacol. Sci.,18, 79–82 (1997).
C. H. V. Hoyle, G. E. Knight, and G. Burnstock,Br. J. Pharmacol.,99, 617–621 (1990).
A. U. Ziganshin, C. H. V. Hoyle, X. Bo, et al.,Br. J. Pharmacol.,110, 1491–1495 (1993).
G. J. McLaren, G. Lambrecht, E. Mutschler, et al.,Br. J. Pharmacol.,111, 913–917 (1994).
J. L. Boyer, I. E. Zohn, K. A. Jacobson, et al.,Br. J. Pharmacol.,113, 614–620 (1994).
J. B. Schater, Q. Li, J. L. Boyer, et al.,Br. J. Pharmacol.,118, 167–173 (1996).
N. J. Cusack,Drug. Dev. Res.,28, 244–252 (1993).
C. H. V. Hoyle,Autonomic Neuroeffector Mechanisms, Harwood Acad. Publ., Chur (1992), pp. 367–407.
L. F. Welford, N. J. Cusack, and S. M. O. Hourani,Eur. J. Pharmacol.,129, 217–224 (1986).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 32, No. 8, pp. 3–4, August, 1998.
Rights and permissions
About this article
Cite this article
Ziganshin, A.U., Rychkov, A.V., Ziganshina, L.E. et al. Some 6-phenylazopyridoxalphosphate derivatives influence P2-purinoreceptor-mediated effects. Pharm Chem J 32, 399–401 (1998). https://doi.org/10.1007/BF02465767
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02465767